We are live on !
Find out more
LCM
Lynx1 Capital Management Portfolio holdings
AUM
$866M
Turnover
27.59%
1-Year Est. Return
231.68%
This Fund
S&P 500
This Quarter Est. Return
+48.07%
1 Year Est. Return
+231.68%
3 Year Est. Return
+883.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$866M
AUM Growth
+$233M
(+37%)
Cap. Flow
+$9.9M
Cap. Flow % of AUM
Cap. Flow %
1.15%
Top 10 Holdings %
Top 10 Hldgs %
98.82%
Holding
29
New
6
Increased
6
Reduced
7
Closed
2
Avg Time Held
0.9
years
Top 10 Avg Time Held
1.4
years
Top 20 Avg Time Held
1.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GH Research
GHRS
|
+$52.2M |
| 2 |
Agios Pharmaceuticals
AGIO
|
+$24.2M |
| 3 |
Pliant Therapeutics
PLRX
|
+$2.19M |
| 4 |
C4 Therapeutics
CCCC
|
+$1.12M |
| 5 |
Traws Pharma
TRAW
|
+$750K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Denali Therapeutics
DNLI
|
+$38.4M |
| 2 |
Stoke Therapeutics
STOK
|
+$23.3M |
| 3 |
Xencor
XNCR
|
+$6.47M |
| 4 |
Immatics
IMTX
|
+$2.05M |
| 5 |
Design Therapeutics
DSGN
|
+$1.27M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
GH Research
GHRS
$1.43B
| $357M | 41.19% |
13,263,288
+2,500,000
| +23% | +$52.2M |
2023 Q2
12 quarters
|
|
2
Cullinan Oncology
CGEM
$967M
| $163M | 18.86% |
8,963,500
| – | – |
2024 Q2
8 quarters
|
|
|
3
Stoke Therapeutics
STOK
$1.7B
| $132M | 15.27% |
4,038,404
-725,269
| -15% | -$23.3M |
2023 Q3
11 quarters
|
|
|
4
Agios Pharmaceuticals
AGIO
$1.82B
| $127M | 14.62% |
3,408,937
+797,369
| +31% | +$24.2M |
2025 Q4
2 quarters
|
|
|
5
C4 Therapeutics
CCCC
$415M
| $34.2M | 3.95% |
7,326,691
+327,789
| +5% | +$1.12M |
2023 Q3
11 quarters
|
|
6
Korro Bio
KRRO
$211M
| $20.3M | 2.34% |
1,538,296
| – | – |
2025 Q4
2 quarters
|
|
7
TScan Therapeutics
TCRX
$11.8M
| $7.86M | 0.91% |
8,019,148
| – | – |
2023 Q2
12 quarters
|
|
8
Precision BioSciences
DTIL
$195M
| $7.47M | 0.86% |
950,466
-34,647
| -4% | -$244K |
2024 Q4
6 quarters
|
|
9
Neuphoria Therapeutics
NEUP
$16.5M
| $3.83M | 0.44% |
875,328
| – | – |
2025 Q4
2 quarters
|
|
10
Passage Bio
PASG
$11.1M
| $3.29M | 0.38% |
673,759
+50,055
| +8% | +$313K |
2022 Q1
17 quarters
|
|
11
CG Oncology
CGON
$5.73B
| $2.23M | 0.26% |
31,391
-200
| -0.6% | -$13.1K |
2025 Q4
2 quarters
|
|
|
12
Pliant Therapeutics
PLRX
$53.2M
| $2.05M | 0.24% |
+1,798,070
| New | +$2.19M |
2026 Q2
0 quarters
|
|
13
Entrada Therapeutics
TRDA
$177M
| $1.31M | 0.15% |
178,606
-33,083
| -16% | -$317K |
2025 Q4
2 quarters
|
|
|
YARW
14
Yarrow Bioscience
YARW
$168M
| $1.06M | 0.12% |
32,574
| – | – |
2026 Q1
1 quarter
|
|
15
ProQR Therapeutics
PRQR
$196M
| $970K | 0.11% |
521,413
+452,927
| +661% | +$746K |
2025 Q4
2 quarters
|
|
|
16
Traws Pharma
TRAW
$4.55M
| $472K | 0.05% |
559,470
+544,392
| +3,611% | +$750K |
2026 Q1
1 quarter
|
|
17
Foghorn Therapeutics
FHTX
$124M
| $301K | 0.03% |
+61,588
| New | +$273K |
2026 Q2
0 quarters
|
|
|
18
Denali Therapeutics
DNLI
$3.03B
| $300K | 0.03% |
11,658
-1,868,645
| -99% | -$38.4M |
2025 Q3
3 quarters
|
|
|
19
Xencor
XNCR
$2.22B
| $293K | 0.03% |
18,194
-518,204
| -97% | -$6.47M |
2025 Q4
2 quarters
|
|
20
Absci
ABSI
$1.91B
| $246K | 0.03% |
21,245
| – | – |
2026 Q1
1 quarter
|
|
21
Werewolf Therapeutics
HOWL
$47.9M
| $237K | 0.03% |
657,786
| – | – |
2025 Q4
2 quarters
|
|
|
22
Immatics
IMTX
$1.1B
| $235K | 0.03% |
23,236
-193,737
| -89% | -$2.05M |
2025 Q4
2 quarters
|
|
23
Avalo Therapeutics
AVTX
$385M
| $187K | 0.02% |
+10,100
| New | +$160K |
2026 Q2
0 quarters
|
|
24
Bolt Biotherapeutics
BOLT
$15.5M
| $119K | 0.01% |
30,800
| – | – |
2026 Q1
1 quarter
|
|
25
Nuvation Bio
NUVB
$1.67B
| $91K | 0.01% |
+16,029
| New | +$78.3K |
2026 Q2
0 quarters
|
|
Similar funds
HP
Lynx1 Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Lynx1 Capital Management held 29 positions worth $866M, up 37% from $633M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Lynx1 Capital Management's Q2 2026 filing shows 6 new, 6 increased, 7 reduced and 2 closed positions. Its largest new stake was Pliant Therapeutics: 1,798,070 shares worth $2.05M. The largest sale was Denali Therapeutics, an estimated $38.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Lynx1 Capital Management's largest Q2 2026 buy was Pliant Therapeutics: 1,798,070 shares worth $2.05M.
- Lynx1 Capital Management added most to GH Research in Q2 2026, an estimated $52.2M increase.
- Lynx1 Capital Management's biggest Q2 2026 reduction was Denali Therapeutics, cutting an estimated $38.4M.
- Lynx1 Capital Management fully exited Design Therapeutics in Q2 2026, selling an estimated $1.27M.
- Lynx1 Capital Management's ten largest holdings make up 99% of its $866M portfolio in Q2 2026.
- Lynx1 Capital Management opened 6 new positions and closed 2 in Q2 2026.
- Lynx1 Capital Management's portfolio value rose 37% quarter-over-quarter to $866M.
Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.